222 related articles for article (PubMed ID: 25537835)
1. Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial.
Ruan Y; Elleri D; Allen JM; Tauschmann M; Wilinska ME; Dunger DB; Hovorka R
Diabetologia; 2015 Apr; 58(4):687-90. PubMed ID: 25537835
[TBL] [Abstract][Full Text] [Related]
2. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial.
Hovorka R; Allen JM; Elleri D; Chassin LJ; Harris J; Xing D; Kollman C; Hovorka T; Larsen AM; Nodale M; De Palma A; Wilinska ME; Acerini CL; Dunger DB
Lancet; 2010 Feb; 375(9716):743-51. PubMed ID: 20138357
[TBL] [Abstract][Full Text] [Related]
3. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial.
Tauschmann M; Allen JM; Nagl K; Fritsch M; Yong J; Metcalfe E; Schaeffer D; Fichelle M; Schierloh U; Thiele AG; Abt D; Kojzar H; Mader JK; Slegtenhorst S; Barber N; Wilinska ME; Boughton C; Musolino G; Sibayan J; Cohen N; Kollman C; Hofer SE; Fröhlich-Reiterer E; Kapellen TM; Acerini CL; de Beaufort C; Campbell F; Rami-Merhar B; Hovorka R;
Diabetes Care; 2019 Apr; 42(4):594-600. PubMed ID: 30692242
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation.
Haidar A; Duval C; Legault L; Rabasa-Lhoret R
J Diabetes Sci Technol; 2013 Nov; 7(6):1507-12. PubMed ID: 24351176
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes.
Herzig D; Dehais J; Prost JC; Nakas CT; Stettler C; Bally L; Hovorka R
Diabetes Technol Ther; 2020 Sep; 22(9):691-696. PubMed ID: 31999478
[No Abstract] [Full Text] [Related]
6. Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.
Dovc K; Piona C; Yeşiltepe Mutlu G; Bratina N; Jenko Bizjan B; Lepej D; Nimri R; Atlas E; Muller I; Kordonouri O; Biester T; Danne T; Phillip M; Battelino T
Diabetes Care; 2020 Jan; 43(1):29-36. PubMed ID: 31575640
[TBL] [Abstract][Full Text] [Related]
7. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
8. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
[TBL] [Abstract][Full Text] [Related]
9. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
[TBL] [Abstract][Full Text] [Related]
10. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
[TBL] [Abstract][Full Text] [Related]
13. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.
Cengiz E; Weinzimer SA; Sherr JL; Tichy E; Martin M; Carria L; Steffen A; Tamborlane WV
Pediatr Diabetes; 2013 May; 14(3):168-73. PubMed ID: 23107353
[TBL] [Abstract][Full Text] [Related]
14. Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.
Cohen E; Tsoukas MA; Legault L; Vallis M; Von Oettingen JE; Palisaitis E; Odabassian M; Yale JF; Garfield N; Gouchie-Provencher N; Rutkowski J; Jafar A; Ghanbari M; Haidar A
Lancet Digit Health; 2024 Jul; 6(7):e489-e499. PubMed ID: 38906614
[TBL] [Abstract][Full Text] [Related]
15. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
[TBL] [Abstract][Full Text] [Related]
16. Comparison between preprandial vs. postprandial insulin aspart in patients with type 1 diabetes on insulin pump and real-time continuous glucose monitoring.
Thuillier P; Sonnet E; Alavi Z; Roudaut N; Nowak E; Dion A; Kerlan V
Diabetes Metab Res Rev; 2018 Sep; 34(6):e3019. PubMed ID: 29749032
[TBL] [Abstract][Full Text] [Related]
17. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.
Hovorka R; Kumareswaran K; Harris J; Allen JM; Elleri D; Xing D; Kollman C; Nodale M; Murphy HR; Dunger DB; Amiel SA; Heller SR; Wilinska ME; Evans ML
BMJ; 2011 Apr; 342():d1855. PubMed ID: 21493665
[TBL] [Abstract][Full Text] [Related]
18. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model.
Petersen SB; Nielsen FS; Ribel U; Sturis J; Skyggebjerg O
J Pharm Pharmacol; 2013 Feb; 65(2):230-5. PubMed ID: 23278690
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery.
Ruan Y; Thabit H; Kumareswaran K; Hovorka R
Comput Methods Programs Biomed; 2014 Nov; 117(2):298-307. PubMed ID: 25092225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
